Inflammatory bowel disease is caused by inappropriate activation of the immune system in response to normal gut bacteria. The two main types are Crohn's disease and ulcerative colitis. Crohn's disease can affect any part of the gastrointestinal tract and often involves transmural inflammation. Ulcerative colitis only involves the colon and rectum in a continuous manner. Both have a genetic component and involve defects in the epithelial barrier and immune response to gut microbiota. Common symptoms include abdominal pain, diarrhea, and weight loss.
This presentation mainly deals with granuloma formation and various factors involved in it. It describes the examples of granulomatous disorders and gives a details on how to seperate them on histopathology.It also describes type 4 hypersensitivty reaction concisely
Chronic myelogenous leukemia (CML) - pluripotential stem cell disease
A malignancy the treatment of which has been revolutionised over the last decade.
Here is a comprehensive discussion on the disease
This presentation mainly deals with granuloma formation and various factors involved in it. It describes the examples of granulomatous disorders and gives a details on how to seperate them on histopathology.It also describes type 4 hypersensitivty reaction concisely
Chronic myelogenous leukemia (CML) - pluripotential stem cell disease
A malignancy the treatment of which has been revolutionised over the last decade.
Here is a comprehensive discussion on the disease
A brief introduction to the IBD and its classification. Mainly dealing here with the Imaging techniques used in the diagnosis of the IBD.
Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. The two major types of inflammatory bowel disease are ulcerative colitis (UC), which is limited to the colon, and Crohn disease (CD), which can affect any segment of the gastrointestinal tract from the mouth to the anus, involves "skip lesions," and is transmural. There is a genetic predisposition for IBD, and patients with this condition are more prone to the development of malignancy.
LOWER GI HEMORRHAGE- PLAYLIST OF 6 VIDEOS
Dear Viewers,
Greetings from “Surgical Educator”.
I have made a playlist for Lower GI Hemorrhage which consists of six videos on various causes of Lower GI Hemorrhage. They are Introduction, diverticular disease, haemorrhoids, fissure-in-ano, colorectal carcinoma and inflammatory bowel disease. If you watch all these videos together you will become confident to tackle the clinical problem of Lower GI Hemorrhage. You can watch these videos in the following link: https://www.youtube.com/playlist…
Thank you for watching the videos.
Inflammatory bowel disease (IBD) is a group of disorders that cause chronic inflammation (pain and swelling) in the intestines. IBD includes Crohn's disease and ulcerative colitis. Both types affect the digestive system. Treatments can help manage this lifelong condition
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
2. INTRODUCTION
Group of inflammatory disorders thought to be
result of inappropriate activation of mucosal
immune system driven by the presence of normal
luminal flora.
Ulcerative Crohn‘s
Two disorders Colitis Disease
1. Crohn‘s disease
2. Ulcerative colitis
INDETERMINATE
COLITIS
3. EPIDEMIOLOGY
Common in Female
Age group – Teens and early 20s
Common in western world
Prevalence increasing in developing nations
4. EPIDEMIOLOGY
Improved food storage
Decreased food contamination
Hygiene Reduced frequency of enteric infection
Hypothes
is Inadequate development of mucosal immune
response regulatory process
Excessive response to self limited diseases
Chronic inflammatory disease
5. EPIDEMIOLOGY
Hygiene hypothesis supported by
Low incidence of IBD in the helminthes
infection prevalent areas
IBD may precedes by an episode of acute
infectious gastroenteritis
6. PATHOGENESIS
Idiopathic Intestinal
Epithelial
disorder Dysfuncti
on
Aberrant Defect in
Mucosal Host
Immune Interaction
Respons with
e Intestinal
Microbiota
10. PATHOGENESIS
NOD2 (Nucleotide oligomerization binding domain
2) Gene
Binds to intracellular bacterial peptidoglycans
Activates NF-kB
In NOD2 Mutation
Luminal microbes are less effectively
recognized
Microbes enter to lamina propria
Trigger inflammatory responses
11.
12. PATHOGENESIS
ATG16L1 (Autophagy-related 16-like) and IRGM
(Immunity-related GTPase M) Gene
Involved in autophagy and clearance of
intracellular bacteria
None of these genes are associated with ulcerative
colitis
18. PATHOGENESIS
Transepitheli
al flux of
luminal
bacterial
components
Activation
Increase
of innate
flux of
and
luminal
adaptive
material
immunity
Increase Secretion of TNF
tight and inflammatory
junction mediator (In
permeabilit genetically
y susceptible Host)
19. PATHOGENESIS
3. Epithelial defects – Critical component
Crohn's disease
Defects in intestinal epithelial tight junction barrier
function
Associated with NOD2 Mutation
Mutation of organic cation transporter SLC22A4
Defect in secreted mucin
21. PATHOGENESIS
4. Microbiota
Varies between individuals and modified by diet
Probiotic may combat disease
Metronidazole and other antibiotics are useful
23. PATHOGENESIS
6. Other Factors
An episode of appendicitis
– Reduce risk of ulcerative colitis
Smoking – Reduces risk of ulcerative colitis
- Increases risk of Crohn's's disease
24. CROHN'S DISEASE
In 850 AD King Alfred, "England's Darling” had a GI
illness that began at age 20 yr
At the time the illness was thought to
be due to punishment for the King's
infidelities. It is now thought to be
Crohn's disease
Louis XIII of France (1601-1643)
25. CROHN'S DISEASE
1913 Dr. Dalziel - Described transmural intestinal
inflammation in 13 autopsied patients.
First fully described and published by
– Crohn's, Ginzburg, Oppenheimer (1932)
Regional enteritis or Granulomatous colitis
26. CROHN'S DISEASE
Equal frequency in both sexes
Common in twenties to thirties
Can manifest in any age from childhood to old age
May occur in any area of GI tract
Most common sites – Terminal ileum
- Iliocecal valve
- Cecum
27. Crohn's’s Disease:
CROHN'S DISEASE
Anatomic Distribution
Small bowel
alone
(33%)
Ileocolic
(45%)
Colon alone
Freq of involvement (20%)
Most Least
28. CROHN'S DISEASE
Gross features
Earliest Crohn's disease lesion – Aphthoid ulcers
Pinpoint reddish
purple erosions
of mucosa
Progress to elongated
serpentine ulcers
29. CROHN'S DISEASE
Gross features
- Sharp demarcation between
normal and abnormal areas
30. CROHN'S DISEASE
Skip lesions – multiple, separate sharply delineated
areas of disease
31. CROHN'S DISEASE
Occasionally entire length of small bowel will be
evolved ( Diffuse jejunoileitis)
Soggy feeling of small bowel
Edema, fibrosis and loss of normal mucosal
architecture
Intramural abscess formation
37. CROHN'S DISEASE
Gross features
Creeping fat – In extensive
transmural disease
extension of mesenteric
fat around the serosal
surface
38. CROHN'S DISEASE
Gross features
Thickened and rubbery
intestinal wall
– Due to transmural edema,
inflammation, submucosal
fibrosis, hypertrophy of
muscularis propria
39. CROHN'S DISEASE
Strictures are common
– Marked narrowing of
lumen along with
dilatation and
hypertrophy of
proximal segment
40. CROHN'S DISEASE
Microscopic features
Submucosal lymphedema – Earliest change
Active disease – Marked infiltration of neutrophils
and destruction of crypt epithelium
Mucosal ulceration, necrosis and atrophy with loss
of crypts
41. CROHN'S DISEASE
Microscopic features
Distortion of mucosal
architecture
– By repeated cycles
of destruction and
regeneration
42. CROHN'S DISEASE
Microscopic features
Lymphoid hyperplasia – Lamina propria and
submucosa
Chronic inflammatory cell infiltrate
Edema, lymphatic dilation, hyperemia along with
hyperplasia of muscularis mucosa
45. CROHN'S DISEASE
Microscopic features
Noncaseating granulomas
Hallmark of Crohn's disease (60% cases)
Sarcoid – like – with in center of lymphoid follicle
Composed of epithelioid cells and multinucleated
giant cells with absent or minimal necrosis
47. CROHN'S DISEASE
Microscopic features
Noncaseating granulomas
– May present anywhere in the wall of bowel, lymph
node, blood vessels (Granulomatous vasculitis)
48. CROHN'S DISEASE
Microscopic features
Fissures – Slit like spaces with sharp edges and
narrow lumina, arranged perpendicularly to the
mucosa and extending
deeply into the
submucosa or even upto
the muscularis externa
49. CROHN'S DISEASE
Microscopic features
Obliterative muscularization
Increase in number of smooth muscle fibers in
submucosa
Stricture formation
Tenascin – Involved in morphogenesis of muscle
tissue and wound healing
Enteritis cystica profunda – Cystically dilated
50. CROHN'S DISEASE
Microscopic features
Disproportionate inflammation – Well defined focus
of inflammatory cells surrounded by noninflamed
and histologically normal mucosa
Mesenteric lymph nodes – May show granuloma
formation
Metastatic Crohn's disease – Formation of
cutaneous granuloma
51. CROHN'S DISEASE
Clinical features
Intermittent attacks of abdominal pain, fever and
mild bloody diarrhea
Mimic acute appendicitis or bowel perforation
Active disease period is interrupted by
asymptomatic periods for weeks to many months
Undulating yet progressive course
52.
53. CROHN'S DISEASE
Clinical features
Reactivation is associated with
– Emotional stress
- Specific dietary items
- Smoking
54.
55. CROHN'S DISEASE
Other associated clinical features
Small bowel disease – Malabsorption
- Sever protein loss
- Hypoalbuminemia
- Vit. B12 deficiency,
Colonic disease - Iron deficiency anemia
56. CROHN'S DISEASE
Clinical features
Extra intestinal manifestation (25%) –
Ocular manifestation – Uveitis
Musculoskeletal system - Migratory polyarthritis
- Osteoporosis
- Ankylosing spondylitis
Skin involvement - Hidradenitis suppurativa
- Clubbing of finger tips
58. CROHN'S DISEASE
Clinical features
Extra intestinal manifestation (25%) –
Hepatobiliary system – Pericolangitis
- Primary sclerosing cholangitis
59. CROHN'S DISEASE
Differential diagnosis
Tuberculosis – Multiple circumferential ulcers
- Caseous necrosis
Sarcidosis - Rarely involve small intestine
- Associated with other systemic features
60. CROHN'S DISEASE
Differential diagnosis
Yersiniosis – Colonies of gram negative bacteria
beneath the ulcers
- Identification of organism in
stool, lymph
node, blood and peritoneal fluid
Eosinophilic enteritis – Peripheral eosinophilia with
61. ULCERATIVE COLITIS
Greek physician Soranus - 130 AD
First officially described by Wilks and Moxon in
1875
Before this discovery, all diarrheal diseases were
believed to be caused by infectious agents and
bacteria
62. ULCERATIVE COLITIS
Severe ulcerating inflammatory disease limited to
colon and rectum
Involves only mucosa and submucosa
Common age group – 20 to 30 yr and 70 to 80 yr
63. ULCERATIVE COLITIS
Gross features
Always involves rectum
Extends proximally in continuous fashion to involve
colon
Limited disease – Ulcerative proctitis
- Ulcerative proctosigmoiditis
- Left sided colitis
- Pancolitis
64. ULCERATIVE COLITIS
Gross features
- Backwash ileitis – Involvement of distal ileum
73. ULCERATIVE COLITIS
Gross features
Mucosal bridges
– Fusion of tips of
Pseudopolyps
74. ULCERATIVE COLITIS
Gross features
Chronic disease – Mucosal atrophy (Flat and
smooth
75. ULCERATIVE COLITIS
Gross features
Submucosal fat deposition
Fibrotic, narrowed and shortened bowel
76. ULCERATIVE COLITIS
Gross features
Toxic megacolon – Due to destruction of muscularis
propria and disturbed
neuromuscular
function due to
inflammation and
inflammatory
mediators - Significant risk of perforation
77. ULCERATIVE COLITIS
Gross features
No stricture formation
No mural thickening
Normal serosal surface
82. ULCERATIVE COLITIS
Microscopic features
Atrophic and regenerative changes present
together
Stromal inflammatory cell infiltrate
83. ULCERATIVE COLITIS
Microscopic features
Pseudopolyps formation - Composed of granulation
tissue mixed with inflamed and hyperemic mucosa
Duplication of muscularis mucosa
Obliterative endarteritis with dilation and
thrombosis of blood vessels
Accumulation of mast cells at the line of
demarcation between normal and abnormal
84. ULCERATIVE COLITIS
Microscopic features
Pseudo pyloric metaplasia
- Presence of gastric antral
appearing glands
85. ULCERATIVE COLITIS
Clinical features
Relapsing and remitting course
Episode of Mucoid bloody diarrhea, lower
abdominal pain and cramp may last for days to
months
Relived by defecation
Triggering factors – Infectious enteritis,
87. ULCERATIVE COLITIS
Clinical features
Extra intestinal manifestations
– Hepatobiliary system - Fatty infiltration
- Liver abscess
- Cirrhosis
- Pericolangitis
- Primary sclerosing cholangitis
- Carcinoma of biliary tract
88. ULCERATIVE COLITIS
Differential diagnosis
Nonspecific bacterial colitis – Acute inflammation
out
of proportion of chronic inflammation
- Absence of crypt distortion
Allergic colitis and proctitis – Mucosal edema and
eosinophilic infiltration
- Common in infants and children
89. ULCERATIVE COLITIS
Differential diagnosis
Pseudomembranous colitis – Presence of yellow
white
mucosal plaques
- Focal explosive mucosal lesion
Cytomegalovirus colitis – inclusion bodies
- Common in immunocompromised patient
91. SEROLOGICAL STUDIES
Anti - neutrophil cytoplasmic antibodies
– Ulcerative colitis (75% cases)
- Crohn's disease (11% cases)
Anti Saccharomyces cerevisiae antibodies
- IgA and IgG against cell wall of Sac.
cerevisiae – Crohn's disease (60% cases)
92. SEROLOGICAL STUDIES
Anti-OmpC*
Anti-Cbir1
Anti-I2
Anti-Glycan Abs
Anti pancreatic Ab (PAB)
Anti-laminaribocide Ab (ALCA)
Anti-chitobioside (ACCA)
93. INDETERMINATE COLITIS
Definitive diagnosis is not possible in 10 % of cases
Pathological and clinical overlap between
Ulcerative colitis and Crohn's disease
Colonic disease in contentious pattern –
Suggestive of ulcerative colitis
Patchy histological disease, fissure, family history
of Crohn's disease, onset after initiating use of
cigarette – Against Ulcerative colitis
94. IBD ASSOCIATED NEOPLASM
Long term complication
Risk factors
Risk increase after 8 to 10 years of disease
initiation
Patient with Pancolitis are at greater risk
Greater frequency and severity of active
inflammation – increase risk (presence of
neutrophils)
95. IBD ASSOCIATED NEOPLASM
Begins with dysplasia and develop into invasive
carcinomas
Categories for dysplasia
1. Negative for dysplasia
2. Indefinite for dysplasia, probably negative
3. Indefinite for dysplasia, unknown
4. Indefinite for dysplasia, probably positive
100. IBD ASSOCIATED NEOPLASM
Adenocarcinoma
Carcinoid tumor
Anaplastic carcinomas
Carcinosarcomas
Malignant lymphomas
Colonic adenomas may also occur
Regular follow-up with mucosal biopsy
101. TREATMENT
Medical – Immunosuppression
- Elemental diet
- Total parenteral nutrition
Surgical management – Resection of involved
bowel segment
102. CROHN'S DISEASE V/S ULCERATIVE COLITIS
Features Crohn's disease Ulcerative colitis
Clinical
Rectal bleeding Inconspicuous Common
Perforation 4% 12%
Colon carcinomaVery rare 5%-10%
Anal 75 %; Fissure, Rare; Minor
complications Fistulas,
Ulceration
Abdominal mass 10%-15% Practically never
Abdominal pain Usually right- Usually left side
sided
103. CROHN'S DISEASE V/S ULCERATIVE COLITIS
Features Crohn's disease Ulcerative colitis
Radiographic
Sparing of 90 % Exceptional
rectum
Involvement of Common; Rare; Dilated
ileum Constricted (Backwash ileitis)
Strictures Often present Absent
Skip areas Common Absent
Internal fistulas May be present Absent
Longitudinal and Common Exceptional
transverse ulcer
104. CROHN'S DISEASE V/S ULCERATIVE COLITIS
Features Crohn's disease Ulcerative colitis
Morphologic
Distribution of Transmural Mucosal and
involvement submucosal
Mucosal atrophy Minimal Marked
and regeneration
Cytoplasmic Preserved Diminish
mucin
Lymphoid Common Rare
aggregates
Edema Marked Minimal
105. CROHN'S DISEASE V/S ULCERATIVE COLITIS
Features Crohn's disease Ulcerative colitis
Morphologic
Hyperemia Minimal May be extreme
Crypt abscesses Rare Common
Rectal 50 % Practically
involvement always
Granulomas Present in 60% Absent
Fissuring Present Absent
Lymph nodes May contain Reactive
granulomas hyperplasia
106. REFERENCES
Rosai and Ackerman’s; surgical pathology
Robbins and Cotran: pathological Basis of Disease
An atlas of gross pathology; C D M Fletcher & P H
McKee
New Concepts in the Pathophysiology of Inflammatory
Bowel Disease ; Annals of Internal Medicine
Harsh Mohan ; Textbook of Pathology
Various internet link
ASCA:Sacch=brewer’s yeastSimple ELISA, standardized, easy to runPoor correlation with mucosal S. cerevesiaeMallant-Hent RC, et al. World J Gastroenterol 2006;12:292 ANCA:ANCA IgG, pANCA IIF, DNASE senspANCA IIFResults variable based on assay, personnel experience. ELISA+IFE--?60%, IFE alone0-40%